ATE446754T1 - Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten - Google Patents
Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeitenInfo
- Publication number
- ATE446754T1 ATE446754T1 AT05732721T AT05732721T ATE446754T1 AT E446754 T1 ATE446754 T1 AT E446754T1 AT 05732721 T AT05732721 T AT 05732721T AT 05732721 T AT05732721 T AT 05732721T AT E446754 T1 ATE446754 T1 AT E446754T1
- Authority
- AT
- Austria
- Prior art keywords
- gluco
- schizophrenia
- compounds
- treatment
- regulatory disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002039 glucoregulatory effect Effects 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/011107 WO2005097122A2 (en) | 2004-04-01 | 2005-04-01 | Method of treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446754T1 true ATE446754T1 (de) | 2009-11-15 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05732721T ATE446754T1 (de) | 2004-04-01 | 2005-04-01 | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (de) |
| EP (2) | EP1734959B1 (de) |
| JP (1) | JP2007531730A (de) |
| KR (1) | KR20070010161A (de) |
| CN (1) | CN1946399A (de) |
| AR (1) | AR048197A1 (de) |
| AT (1) | ATE446754T1 (de) |
| AU (1) | AU2005231446A1 (de) |
| BR (1) | BRPI0509512A (de) |
| CA (1) | CA2561162A1 (de) |
| CL (1) | CL2009001605A1 (de) |
| CY (1) | CY1109734T1 (de) |
| DE (1) | DE602005017373D1 (de) |
| DK (1) | DK1734959T3 (de) |
| DO (1) | DOP2005000050A (de) |
| ES (1) | ES2334241T3 (de) |
| GT (1) | GT200500063A (de) |
| IL (1) | IL178168A0 (de) |
| MX (1) | MXPA06011222A (de) |
| PA (1) | PA8628601A1 (de) |
| PL (1) | PL1734959T3 (de) |
| PT (1) | PT1734959E (de) |
| SI (1) | SI1734959T1 (de) |
| SV (1) | SV2006002069A (de) |
| TW (1) | TW200602040A (de) |
| WO (1) | WO2005097122A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| RU2009117605A (ru) * | 2006-10-12 | 2010-11-20 | Ксенон Фармасьютикалз Инк. (Ca) | ПРОИЗВОДНЫЕ СПИРО-(ФУРО[3,2-c]ПИРИДИН-3-3'-ИНДОЛ)-2'(1'H)-ОНА И РОДСТВЕННЫЕ ИМ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ НАТРИЕВЫМИ КАНАЛАМИ ЗАБОЛЕВАНИЙ, ТАКИХ КАК БОЛЬ |
| WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010045251A2 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| JP5714572B2 (ja) * | 2009-06-03 | 2015-05-07 | マーケット ユニバーシティー | 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| AU2010306768B2 (en) | 2009-10-14 | 2016-08-04 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| MY165117A (en) | 2010-02-26 | 2018-02-28 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| EP4516356A3 (de) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Verwendung von pridopidin zur behandlung von funktionalem verfall |
| AU2020242978B2 (en) * | 2019-03-19 | 2025-10-02 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| EP0840609B1 (de) * | 1995-07-27 | 2002-06-05 | Aventis Pharmaceuticals Inc. | Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva |
| EP0876379A1 (de) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Kondensierte 1,2,4-thiadiazin- und 1,4-thiazinderivate, deren herstellung und verwendung |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| JP2001510195A (ja) | 1997-07-16 | 2001-07-31 | ノボ ノルディスク アクティーゼルスカブ | 縮合化１，２，４−チアジアジン誘導体、その調製及び使用 |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de not_active Expired - Lifetime
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Ceased
- 2005-04-01 EP EP05732721A patent/EP1734959B1/de not_active Expired - Lifetime
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es not_active Expired - Lifetime
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en not_active Ceased
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 EP EP09012248A patent/EP2138176A1/de not_active Withdrawn
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR048197A1 (es) | 2006-04-05 |
| DE602005017373D1 (de) | 2009-12-10 |
| PA8628601A1 (es) | 2006-05-16 |
| IL178168A0 (en) | 2006-12-31 |
| US20070129403A1 (en) | 2007-06-07 |
| JP2007531730A (ja) | 2007-11-08 |
| SV2006002069A (es) | 2006-05-24 |
| ES2334241T3 (es) | 2010-03-08 |
| BRPI0509512A (pt) | 2007-09-11 |
| TW200602040A (en) | 2006-01-16 |
| CL2009001605A1 (es) | 2009-11-27 |
| DOP2005000050A (es) | 2005-11-30 |
| EP1734959A2 (de) | 2006-12-27 |
| CN1946399A (zh) | 2007-04-11 |
| AU2005231446A1 (en) | 2005-10-20 |
| KR20070010161A (ko) | 2007-01-22 |
| EP1734959B1 (de) | 2009-10-28 |
| CY1109734T1 (el) | 2014-09-10 |
| PL1734959T3 (pl) | 2010-03-31 |
| CA2561162A1 (en) | 2005-10-20 |
| PT1734959E (pt) | 2009-12-24 |
| WO2005097122A2 (en) | 2005-10-20 |
| SI1734959T1 (sl) | 2010-02-26 |
| GT200500063A (es) | 2005-10-14 |
| DK1734959T3 (da) | 2010-03-08 |
| EP2138176A1 (de) | 2009-12-30 |
| WO2005097122A3 (en) | 2006-02-02 |
| MXPA06011222A (es) | 2007-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006018583D1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| DE602006019838D1 (de) | Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten | |
| DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
| EP1916964A4 (de) | Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten | |
| ATE519488T1 (de) | Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten | |
| DE602006019560D1 (de) | 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen | |
| ATE446754T1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| EP2007393A4 (de) | Thiazol- und thiophen-analoga sowie ihre verwendung zur behandlung von autoimmunerkrankungen und karzinomen | |
| EP1742675A4 (de) | Behandlung von biomedizinischem abfall | |
| DE60335293D1 (de) | Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen | |
| EP1851237A4 (de) | Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| DE602006006354D1 (de) | Pinolensäure zur Behandlung von Übergewicht | |
| DE602005017503D1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| DE602004003952D1 (de) | Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
| EP1905452A4 (de) | Wirkstoff zur prävention oder behandlung von glaukomen | |
| DE602004001134D1 (de) | Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit | |
| DE602005023452D1 (de) | Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte | |
| DE602004019576D1 (de) | Zur behandlung von schmerzen geeignete piperazine | |
| ATE504297T1 (de) | Visnadin zur behandlung von kopfhautjucken | |
| DE602005014145D1 (de) | Medikamente zur behandlung oder prävention fibrotischer krankheiten | |
| DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1734959 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |